GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
GO:00107209 | Oral cavity | OSCC | positive regulation of cell development | 159/7305 | 298/18723 | 3.06e-07 | 4.66e-06 | 159 |
GO:00063563 | Oral cavity | OSCC | regulation of transcription by RNA polymerase I | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:00063601 | Oral cavity | OSCC | transcription by RNA polymerase I | 36/7305 | 55/18723 | 6.42e-05 | 5.22e-04 | 36 |
GO:00459431 | Oral cavity | OSCC | positive regulation of transcription by RNA polymerase I | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
GO:000854416 | Oral cavity | LP | epidermis development | 112/4623 | 324/18723 | 3.81e-05 | 5.61e-04 | 112 |
GO:001072014 | Oral cavity | LP | positive regulation of cell development | 93/4623 | 298/18723 | 6.07e-03 | 3.60e-02 | 93 |
GO:000854425 | Skin | cSCC | epidermis development | 131/4864 | 324/18723 | 7.38e-09 | 2.39e-07 | 131 |
GO:00063565 | Skin | cSCC | regulation of transcription by RNA polymerase I | 22/4864 | 34/18723 | 2.33e-06 | 3.77e-05 | 22 |
GO:00063603 | Skin | cSCC | transcription by RNA polymerase I | 30/4864 | 55/18723 | 6.13e-06 | 8.70e-05 | 30 |
GO:00459433 | Skin | cSCC | positive regulation of transcription by RNA polymerase I | 15/4864 | 23/18723 | 8.72e-05 | 8.21e-04 | 15 |
GO:001072016 | Skin | cSCC | positive regulation of cell development | 105/4864 | 298/18723 | 2.30e-04 | 1.89e-03 | 105 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BNC1 | SNV | Missense_Mutation | | c.1702C>A | p.Pro568Thr | p.P568T | Q01954 | protein_coding | deleterious(0.04) | benign(0.058) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
BNC1 | SNV | Missense_Mutation | | c.1220N>T | p.Ala407Val | p.A407V | Q01954 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
BNC1 | SNV | Missense_Mutation | rs766072426 | c.2911C>T | p.Arg971Cys | p.R971C | Q01954 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BNC1 | SNV | Missense_Mutation | rs767533958 | c.2918G>A | p.Arg973Gln | p.R973Q | Q01954 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
BNC1 | SNV | Missense_Mutation | | c.2821N>A | p.Gly941Arg | p.G941R | Q01954 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
BNC1 | SNV | Missense_Mutation | | c.320N>A | p.Arg107His | p.R107H | Q01954 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BNC1 | SNV | Missense_Mutation | rs149687703 | c.1576N>A | p.Glu526Lys | p.E526K | Q01954 | protein_coding | tolerated(0.12) | benign(0.057) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
BNC1 | SNV | Missense_Mutation | | c.2008G>A | p.Asp670Asn | p.D670N | Q01954 | protein_coding | tolerated(0.16) | benign(0) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BNC1 | SNV | Missense_Mutation | | c.2491N>C | p.Val831Leu | p.V831L | Q01954 | protein_coding | deleterious(0.03) | benign(0.184) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
BNC1 | SNV | Missense_Mutation | | c.548T>A | p.Met183Lys | p.M183K | Q01954 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |